We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Genome and drug researcher Perlegen Sciences Inc. of Mountain View, Calif.,
has received the third-largest venture funding round of 2005, a $74 million
private placement intended to shore up its late-stage drug pipeline.
Sigma-Aldrich Corp. has completed its $370 million
cash acquisition of JRH Biosciences division of CSL Ltd., it said. Lenexa, Kan.-based
JRH Biosciences supplies cell culture and sera products to the biopharmaceutical
industry.
FDA has approved Vaccinia Immune Globulin Intravenous (VIGIV), the first intravenous
human plasma-derived product available to treat certain rare complications of
smallpox vaccination.
Novartis is facing a $100 million sex-discrimination
lawsuit initiated by 12 former and current employees who claim the company has
a "systematic pattern" of discriminating against women.
Novartis has agreed to purchase German generic drugmaker Hexal AG and U.S. generic
company Eon Labs -- acquisitions that will make it the largest generic drug company
in the world, the company said.
Evotec OAI AG, a leading partner for integrated high-value-added drug discovery
and development solutions to the pharmaceutical and biotechnology industries,
has announced that it will support Mitsubishi Pharma, Osaka, Japan, in its medicinal
chemistry programs.
Integrated systems biology company Icoria has licensed to Syngenta the exclusive
rights to commercially develop 30 Icoria compounds believed to be active fungal
inhibitors.
Drugmaker Bradley Pharmaceuticals Inc. reported Monday that the Securities and
Exchange Commission launched an informal probe to determine if the company violated
securities laws.